Articles tagged with Agonists
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly lowers risks of limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared to dipeptidyl peptidase-4 inhibitors in patients with diabetes. GLP-1 RAs are preferred for secondary prevention in this high-risk population.
After initiating GLP-1 receptor agonists, consumers showed a decrease in ultraprocessed foods and an increase in protein, while purchasing fewer calories, sugars, and saturated fats. These modest changes may have significant population-level effects given increasing GLP-1RA use.
A comparative effectiveness study found that SGLT2 inhibitors were associated with a lower risk of chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists. These findings suggest that SGLT2 inhibitor treatment may be an effective strategy for preventing kidney disease in individuals with type 2 diabetes.
Both bariatric surgery and semaglutide treatment were associated with significant fat mass loss, moderate fat-free mass loss, and an improved FFM to fat mass ratio. These findings support interventions aimed at preserving muscle mass while promoting weight loss.
A study found that women with obesity who stopped using GLP-1 receptor agonists experienced more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders. The research suggests that discontinuation of these medications may impact pregnancy outcomes.
Withdrawal of tirzepatide after 36-week treatment led to 25% or greater weight regain in most participants within a year, reversing initial cardiometabolic parameter improvements. Continued obesity treatment is crucial for sustained benefits.
The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.
A cohort study found that GLP-1 receptor agonist use was associated with a reduced risk of developing nonexudative AMD, but not progression to exudative AMD in individuals with nonexudative AMD. This study may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
This study found that GLP-1RAs and SGLT2is offer the greatest cardiovascular benefits for adults with type 2 diabetes. The magnitude of benefit depends on baseline age, atherosclerotic cardiovascular disease, heart failure, and kidney impairment.
A cohort study found that 40% of GLP-1RA orders were not filled, with lower rates among Non-Hispanic Black and Hispanic patients. These disparities may be attributed to differences in insurance coverage, GLP-1RA use, or cost thresholds.
A binational study found nearly 6 in 10 US adults and 3 in 10 Japanese adults discontinued semaglutide within 12 months of treatment. Patients with established cardiovascular disease and chronic kidney disease had higher discontinuation rates, highlighting the need for alternative treatments.
Prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal, leading to substantial out-of-pocket costs. Out-of-pocket costs for GLP-1RAs rose significantly from 2020 to 2025, affecting many high-cost drugs.
Metabolic bariatric surgery shows promise as a cost-effective weight loss option for class II and III obesity patients. The study found bariatric surgery resulted in greater weight loss compared to GLP-1 receptor agonists.
A systematic review and meta-analysis of 18 trials found GLP-1 RAs significantly improved glycemic and weight outcomes in children and adolescents with type 2 diabetes or obesity. However, gastrointestinal adverse effects warrant attention in long-term management.
A cohort study found GLP-1 RAs offer body mass index-dependent cardiovascular benefits and consistent kidney protection for type 2 diabetes patients. The study suggests BMI stratification is crucial for guiding treatment decisions.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
Cohort study finds GLP-1 receptor agonist use associated with modestly increased risk of incident diabetic retinopathy; however, those with preexisting DR experience fewer sight-threatening complications. Regular screening and monitoring recommended for all T2D patients on GLP-1 RAs.
A study found that semaglutide and liraglutide use are associated with a higher risk of nonarteritic anterior ischemic optic neuropathy in older patients with type 2 diabetes. The GLP-1 receptor agonists showed varying levels of risk, with liraglutide posing the greatest threat.
A recent study published in JAMA Network Open found that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment was associated with reduced all-cause mortality among older patients with cancer and type 2 diabetes. The survival benefit persisted across various subgroups, including age, sex, and cancer type.
A cohort study found that GLP-1RAs like semaglutide and tirzepatide lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. The findings suggest potential neuroprotective benefits beyond glycemic control.
The article provides practical strategies for managing symptoms in patients receiving GLP-1 RAs, focusing on diet and physical activity interventions to support muscle and nutrient preservation. Lifestyle factors remain crucial in GLP-1 RA treatment for effective weight management.
A new study found significant reductions in medication use, symptoms, and procedural interventions with GLP-1 receptor agonist therapy for idiopathic intracranial hypertension. Further prospective studies are needed to confirm these findings.
A team of researchers from The University of Osaka has made a breakthrough in weight loss treatment by developing a one-time genome editing approach that introduces a GLP-1 receptor agonist gene. This innovative method enables the body to produce its own weight-loss medication, reducing the need for regular injections.
The use of GLP-1 receptor agonists among diabetes patients is associated with a higher risk of developing incident neovascular age-related macular degeneration. Further research is needed to understand the underlying mechanisms and trade-offs between benefits and risks.
GLP1-RA treatment is associated with improvements in quality of life, restrained eating, and emotional eating behavior. The treatment also provides reassurance regarding its psychiatric safety profile.
A study by Helmholtz Munich researchers found that GIPR agonism and antagonism decrease body weight and food intake via different mechanisms. GIPR agonists use GABAergic neurons to exert their effect, while antagonists rely on the GLP-1 receptor signal.
The study estimates that expanded Medicare coverage for GLP-1RAs would increase access to these treatments and reduce obesity-related comorbidities. However, this would come with substantial costs over a decade, projected at $8 billion, highlighting the need for further price reductions and cost-saving strategies.
A new study in The Lancet Public Health finds that safer supply programs complement existing treatment options for people struggling with opioid use disorder. Safer supply programs provide pharmaceutical-grade opioids to reduce overdose rates, healthcare utilization, and costs.
A recent study published in Current Neuropharmacology suggests a potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists and depression, particularly in individuals with low dopamine function. The authors urge caution and recommend genetic testing to identify individuals at risk before prescribing these medications.
A study published by the European Association for the Study of Obesity found that women are significantly more aware of and have a better understanding of obesity drugs like semaglutide and tirzepatide. Understanding tolerable side effects, effectiveness, and ability to maintain weight loss is crucial for people commencing treatment.
A six-month study found that patients using GLP-1 and dual GLP-1/GIP receptor agonist therapy experienced minimal lean muscle mass loss as they lost weight. Regular resistance training, consistent protein intake, and close supervision by an expert obesity doctor were associated with better muscle retention.
A meta-analysis of randomized clinical trials found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a statistically significant reduction in all-cause dementia. Cardioprotective glucose-lowering therapies, however, did not show an overall reduction in dementia risk.
Research reveals that GLP-1RAs and SGLT2i medications significantly reduce the risk of Alzheimer's disease and related dementias in people with type 2 diabetes. No significant difference was found between these two treatments.
A study found that spending on GLP-1 RAs increased from 2018 to 2023, with the largest growth rate between 2022 and 2023. The total spending on these medications exceeded $71 billion.
A study published in Diabetes, Obesity and Metabolism found that obesity rates among type 1 diabetes patients increased for all age groups and ethnicities from 2008 to 2023. GLP-1 receptor agonist use also rose sharply, with a sevenfold increase in severely obese youth with type 1 diabetes between 2008-11 and 2020-23.
A study found no increased risk of suicidal events among adults taking GLP-1 receptor agonists for diabetes or obesity, but continued monitoring is warranted to identify at-risk patients. The findings ease concerns about these potential adverse effects, allowing extended use of GLP-1 RAs.
A cohort study found no significant association between preoperative GLP-1 RA use and short-term postoperative aspiration pneumonia. The study suggests reassessing preoperative withholding guidelines for GLP-1 RAs. Researchers hope this finding can help alleviate growing concerns about adverse effects of these medications after surgery.
A synthetic retinoic acid-inducible gene I (RIG-I) agonist RNA has been shown to induce innate immune signaling and death of hepatocellular carcinoma cells in vitro. The addition of recombinant interferon-b potentiated this cell death, suggesting a potential new mechanism for treating patients with liver cancer.
Sodium-glucose cotransporter-2 inhibitors and GLP-1RAs show reduced risk of moderate/severe COPD exacerbations compared to dipeptidyl peptidase 4 inhibitors. This finding may inform glucose-lowering medication prescribing for patients with type 2 diabetes and active COPD.
Researchers at Tokyo University of Science have found that opioid delta-receptor agonists can alleviate stress-induced IBS symptoms in a validated mouse model by targeting the central nervous system. The study suggests that these drugs could provide a more definitive solution for IBS with minimal adverse effects.
A systematic review and network meta-analysis of 601 trials revealed that SGLT2 inhibitors were more cardioprotective in older adults, while GLP-1 receptor agonists offered greater benefits to younger patients. These findings suggest personalized treatment approaches for type 2 diabetes based on age and sex.
A cohort study found that patients without type 2 diabetes had higher discontinuation rates and lower reinitiation rates of GLP-1 receptor agonist therapy. Inequities in access and adherence to effective treatments exacerbate disparities in obesity.
The study found a significant increase in obesity drug prescriptions from 0.76 million in July 2017 to 1.5 million in February 2024, mirroring rising public online search activity for semaglutide and tirzepatide. This correlation highlights the real-time association between public awareness and prescription trends.
A new microdosing approach using low doses of buprenorphine has been tested on patients with opioid use disorder, but most found it ineffective. The study, which included 126 participants, showed that only 34% were able to work up to a full dose of buprenorphine.
A large population-based analysis found that genetic variants in the GLP1R gene are associated with cardiometabolic traits and behavioral changes, such as risk-taking behavior and anxiety. These findings suggest that any observed behavioral changes with GLP1RA medications are unlikely to be a direct result of the medication.
Researchers at Nagoya University found that stimulating CB2 with JWH 133 improved cognitive function and reduced neuroinflammation in AD mouse models. The study suggests that CB2 is a potential therapeutic target for Alzheimer's disease, providing a cost-effective alternative to existing treatments.
A cohort study found that insurance plan type and structure play a crucial role in determining access to semaglutide for adults with obesity. The findings suggest that targeted interventions at the insurance level could improve equity in obesity treatment access.
A cross-sectional study found that websites selling compounded glucagon-like peptide-1 receptor agonists often misinformed potential consumers about the medications' safety, efficacy, and FDA approval status. The study highlights the need for increased transparency and regulation in the online advertising of these medications.
A new study reveals that delta opioid receptor agonist KNT-127 has a rapid and effective antidepressant effect with minimal side effects. The research highlights the molecular mechanisms underlying its action, including mTOR signaling pathways and Akt activation in the medial prefrontal cortex.
A large international study of GLP1-RA users and dipeptidyl peptidase-4 inhibitors (DPP-4i) found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer. The study, published in the Thyroid journal, analyzed data from 92,497 GLP1-RA users and 2,484,408 DPP-4i users.
Researchers developed a method to distinguish between similar odours by detecting small electrical changes in olfactory receptors. This innovation enables more precise sensors for industrial applications, such as odour screening.
Adult obesity trends in the US have declined for the first time in more than a decade, according to recent data. The South region experienced the largest decreases in body mass index and obesity prevalence, despite also facing high COVID-19 mortality rates among obese individuals.
A cohort study found that nearly half of participants who consumed alcohol at baseline decreased their alcohol use after initiating anti-obesity medication treatment. The medications, such as naltrexone and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may have properties that lead to reduced cravings for alcohol.
The discontinuation of GLP-1 RAs has significant clinical implications, including reduced glucose control and increased cardiovascular risk. Long-term adherence to these therapies is crucial for optimal patient outcomes.
A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.
A cross-sectional study found a significant increase in GLP-1 receptor agonist (RA) use as anti-obesity medications from 2022 to 2023. Meanwhile, the rate of metabolic bariatric surgery decreased by 25.6% during the same period. These findings suggest a potential shift in treatment strategies for obesity management
The use of GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors in people with type 1 diabetes has significantly increased between 2010 and 2023. This trend is driven by their benefits in weight management and cardiorenal protection, but caution is advised due to concerns about euglycemic diabetic ketoacidosis.
Two studies found that bariatric surgery is more cost-effective in the long term compared to GLP-1 RA weight loss drugs alone. Combining both treatments is even more cost-effective. The use of GLP-1 RA before surgery appears safe and may be a novel approach to treating obesity.
A new study found that people with opioid or alcohol use disorder who take Ozempic or similar medications have a lower rate of opioid overdose and alcohol intoxication. The medication, which treats diabetes and weight-related conditions, may also alter the brain's reward-response pathways associated with substance use.
A new study found that GLP1 receptor agonists reduce the risk of suicidal ideation or attempts in adolescents with obesity. The treatment, compared to lifestyle intervention, showed a favorable psychiatric safety profile and potential avenues for future research.